What is HC Wainwright’s Estimate for TARS Q1 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Tarsus Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst O. Livnat anticipates that the company will post earnings of ($0.80) per share for the quarter. HC Wainwright has a “Buy” rating and a $73.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.59) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at $1.52 EPS, FY2026 earnings at $1.52 EPS, FY2027 earnings at $4.14 EPS and FY2027 earnings at $4.14 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million.

Several other equities research analysts have also issued reports on TARS. Barclays lowered their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday. The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Guggenheim reissued a “buy” rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Finally, Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Trading Up 2.1 %

Shares of Tarsus Pharmaceuticals stock opened at $44.48 on Friday. The firm has a market capitalization of $1.71 billion, a PE ratio of -11.67 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The company’s fifty day moving average price is $50.97 and its two-hundred day moving average price is $43.25. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP grew its holdings in shares of Tarsus Pharmaceuticals by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company’s stock worth $140,191,000 after purchasing an additional 91,451 shares during the last quarter. Jennison Associates LLC lifted its position in Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after buying an additional 321,552 shares in the last quarter. Vanguard Group Inc. lifted its position in Tarsus Pharmaceuticals by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company’s stock worth $117,117,000 after buying an additional 17,839 shares in the last quarter. Toronto Dominion Bank acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $105,714,000. Finally, Lord Abbett & CO. LLC lifted its position in Tarsus Pharmaceuticals by 115.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock worth $70,873,000 after buying an additional 685,111 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.